IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Novartis be gan trad ing on the New York Stock Ex change.
• Year: 1999
Eu ro pean reg u la tory au thor i ties granted Barilla (It aly) per mis sion to ac quire Novartis’ Wasa crisp breads
sub sid iary for SFr475 million.
Novartis an nounced plans to make Novartis Sci en tific Ser vices an in de pend ent com pany. The unit of fers
sci en tific and tech ni cal ser vices to the phar ma ceu ti cal and chem i cal industries.
Novartis sold its 51% in ter est in OLW Snacks (Swe den), its 49% in ter est in Chips OLS (Swe den), its
100% stake in the Eden Group (Ger many), and its 100% in ter est in Wasa op er a tions in Swe den, Ger -
many, Den mark, Nor way and Po land. The sale price for these divestments (all part of Con sumer Health)
to taled SFr625 million.
• Year: 1998
The Generics sec tor ac quired the an ti bi ot ics and the Frank furt fer men ta tion plant of Hoechst Marion
Roussel (now sanofi-aventis, France).
Agreed to sell sev eral Ital ian sugar-free con fec tion ery brands to Compagnie Industriali Riunite SpA (It -
aly).
Novartis was one of a num ber of ma jor phar ma ceu ti cal com pa nies to fund the Cen ter for Bio med i cal Ac -
cel er ated Mass Spec trom e try near York, Eng land, opened late in 1998.
The Novartis Re search Foun da tion an nounced the cre ation of the Novartis In sti tute for Func tional
Genomics, a re search cen ter de voted en tirely to func tional genomics, the study of the re la tion ships be -
tween par tic u lar ge no types and dis ease states, in La Jolla, California.
Novartis an nounced plans to close or sell 35 of its 62 plants world wide, with a loss of over 1,000 jobs.
Most of the di vest ing was in Asia and the USA as Novartis con cen trates its ac tiv i ties in Eu rope, but five of
14 Eu ro pean plants were also closed. All chem i cal pro duc tion was halted in the USA and Asia.
• Year: 1997
Novartis an nounced plans to con sol i date its op er a tions in South Ko rea via the sep a ra tion and in te gra tion
of Ciba’s stake in the ex ist ing Searle Ciba-Geigy jv. Searle Ciba-Geigy, in which the two com pa nies had
stakes of 45% and lo cal part ners hold 10%, was dis solved and split into two sep a rate en ti ties. Ciba’s op -
er a tions, prod ucts and staff were trans ferred to Novartis. Sandoz’ ex ist ing op er a tions in the coun try were
merged with those of Ciba to form a wholly-owned subsidiary.
Thermo Ecotek Corp (USA) ac quired Novartis’ Ba cil lus thuringiensis-biopesticide prod uct lines for $19.1
mil lion.
Novartis es tab lished a Foun da tion for Ge ron to log i cal Re search.
Walden (USA), a pri vate eq uity fund, took a stake in the Ciba CKD Biochem joint ven ture. Af ter the place -
ment Novartis, Hindustan Ciba-Geigy (In dia) and Chong Kun Dang (South Ko rea) held a 51% stake be -
tween them.
• Year: 1995
Ciba an nounced plans for an an ti bi ot ics man u fac tur ing jv with CKD (South Ko rea), tak ing a 51% stake.
© 2009 IMS Health In cor po rated or its af fil i ates Page 145